Table 1.
First Author (no. of subjects) [References] | Clinical failured | Microbiologic failured | Mortality | Combination antimicrobial therapy | ||||||
---|---|---|---|---|---|---|---|---|---|---|
PMB/COL | TCN | AMG | CARB | FOS | PCN | FQ | ||||
Ariza-Heredia (n = 1) [18] | – | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
Balandin Moreno (n = 3) [31] | – | 2/3 (66.7%) | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) | 1/3 (33.3%) | 2/3 (66.7%) | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
Camargo (n = 1) [19] | – | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
Chuaa (n = 2) [20] | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
Cicora (n = 5) [32] | – | 4/5 (80%) | 1/5 (20%) | 3/5 (60%) | 5/5 (100%) | 0/5 (0%) | 3/5 (60%) | 4/5 (80%) | 0/5 (0%) | 0/5 (0%) |
Clancy (n = 1) [33] | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
de Sanctis (n = 1) [21] | – | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
Giamarellou (n = 1) [22] | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) |
Lemmenmeier (n = 3) [23] | 0/3 (0%) | – | 0/3 (0%) | 3/3 (100%) | 3/3 (100%) | 0/3 (0%) | 3/3 (100%) | 0/3 (0%) | 0/3 (0%) | 0/3 (0%) |
Lubbert (n = 4) [37] | 3/4 (75.0%) | – | 3/4 (75%) | 4/4 (100%) | 4/4 (100%) | 4/4 (100%) | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
Maltezou (n = 2) [38] | 0/2 (0%) | 2/2 (100%) | 0/2 (0%) | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
Marquezb (n = 1) [24] | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
Mathersc (n = 1) [25] | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) |
Morris (n = 1) [39] | 0/1 (0%) | – | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
Mouloudi (n = 4) [40] | 1/4 (25.0%) | 1/4 (25%) | 2/4 (50%) | 4/4 (100%) | 4/4 (100%) | 4/4 (100%) | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
Navarro (n = 2) [41] | – | – | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) | 2/2 (100%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
Nevrekar (n = 1) [26] | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
Olivaa (n = 1) [27] | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
Pontikis (n = 9) [28] | 5/9 (55.6%) | 4/9 (44.4%) | 4/9 (44.4%) | 8/9 (88.9%) | 4/9 (44.4%) | 2/9 (22.2%) | 3/9 (33.3%) | 9/9 (100%) | 2/9 (22.2%) | 0/9 (0%) |
Sanchez-Romero (n = 1) [47] | – | – | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
Souli (n = 6) [43] | 3/6 (50%) | 3/6 (50%) | 5/6 (83.3%) | 6/6 (100%) | 3/6 (50%) | 3/6 (50%) | 4/6 (66.7%) | 0/6 (0%) | 2/6 (33.3%) | 2/6 (33.3%) |
Viaggi (n = 1) [29] | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) |
Virgilio (n = 1) [30] | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) | 0/1 (0%) | 0/1 (0%) |
N = 53 | 14/39 (35.9%) | 22/42 (52.4%) | 19/53 (35.8%) | 47/53 (88.6%) | 39/53 (73.6%) | 26/53 (49.1%) | 23/53 (43.4%) | 16/53 (30.2%) | 5/53 (9.4%) | 4/53 (7.5%) |
PMB polymyxin B, COL colistin, TCN tetracycline, AMG aminoglycoside, CARB carbapenem, FOS fosfomycin, PCN penicillin, FQ fluoroquinolone
aDual carbapenem therapy used
bRifampin also administered
cTrimethoprim–sulfamethoxazole also administered
dDash indicates information was unavailable